{"nctId":"NCT01272193","briefTitle":"Comparison of NN5401 With Insulin Glargine in Insulin Naive Subjects With Type 2 Diabetes","startDateStruct":{"date":"2011-01"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":296,"armGroups":[{"label":"IDegAsp OD","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/insulin aspart","Drug: insulin glargine"]},{"label":"IGlar OD","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine"]}],"interventions":[{"name":"insulin degludec/insulin aspart","otherNames":[]},{"name":"insulin glargine","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months\n* HbA1c 7.0-10.0% (both inclusive) by central laboratory analysis\n* Body Mass Index (BMI) below or equal to 35.0 kg/m\\^2\n* Insulin naive subject and ongoing treatment with 1 or more oral antidiabetic drugs (OADs) for at least 12 weeks prior to randomisation with at least recommended maintenance dose according to local, approved labelling Allowed are: a. Previous short term insulin treatment up to 14 days; b. Treatment during hospitalization or during gestational diabetes is allowed for periods longer than 14 days)\n\nExclusion Criteria:\n\n* Anticipated change in concomitant medication known to interfere significantly with glucose metabolism, such as systemic corticosteroids, beta-blockers, mono amino oxidase (MAO) inhibitors\n* Use of glucagon-like peptide-1 (GLP-1) receptor agonists, buformine and/or rosiglitazone within the last 12 weeks prior to randomisation\n* Cardiovascular disease, within the last 6 months prior to Visit 1, defined as: stroke; decompensated heart failure New York Heart Association (NYHA) class III or IV; myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or angioplasty","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Glycosylated Haemoglobin (HbA1c)","description":"Observed change from baseline in HbA1c after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.35","spread":"0.86"},{"groupId":"OG001","value":"-1.22","spread":"0.98"}]}]}]},{"type":"SECONDARY","title":"Mean Increment of 9-point Self Measured Plasma Glucose Profile (SMPG) at the Main Evening Meal","description":"Observed mean increment of the 9-point self-measured plasma glucose profile (SMPG) at the main evening meal","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"4.2"},{"groupId":"OG001","value":"4.7","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Rate of Treatment Emergent Adverse Events (AEs)","description":"Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"334","spread":null},{"groupId":"OG001","value":"368","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"316","spread":null},{"groupId":"OG001","value":"353","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Confirmed Hypoglycaemic Episodes","description":"Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"191","spread":null},{"groupId":"OG001","value":"271","spread":null}]}]}]},{"type":"SECONDARY","title":"Rate of Nocturnal Confirmed Hypoglycaemic Episodes","description":"Observed rate of confirmed hypoglycaemic episodes per 100 patient years of exposure (PYE). Confirmed hypoglycaemic episodes consisted of severe hypoglycaemia as well as minor hypoglycaemic episodes. Severe hypoglycaemic episodes were defined as requiring assistance to administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as able to treat her/himself and plasma glucose below 3.1 mmol/L. Nocturnal hypoglycaemic episodes were defined as occurring between 00:01 and 05:59 a.m.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"53","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Observed change from baseline in body weight after 26 weeks of treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"2.8"},{"groupId":"OG001","value":"0.7","spread":"2.2"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":147},"commonTop":["Nasopharyngitis","Diabetic retinopathy"]}}}